Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

AAPHARMASYN LLC

UEI: YUFFPW8FVKX2CAGE: 6NX94

AAPHARMASYN LLC is a federal contractor, registered under UEI YUFFPW8FVKX2 and CAGE code 6NX94. It has been awarded $1,063,624 across 12 federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology), Research and Development in Nanotechnology, and Research and Development in Biotechnology. Top awarding agencies include Department Of Health And Human Services and Department Of Defense.

Contact Information

Registration and classification details

Registration

UEI Code

YUFFPW8FVKX2

CAGE Code

6NX94

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

272XLJ

NAICS Codes

325180Other Basic Inorganic Chemical Manufacturing
325199All Other Basic Organic Chemical Manufacturing
541380Testing Laboratories and Services
541713Research and Development in Nanotechnology
541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

AAPHARMASYN LLC specializes in scientific research and development services, primarily supporting federal initiatives through advanced pharmaceutical and life sciences innovation. Leveraging deep expertise in process development, analytical method validation, and regulatory-compliant formulation sci...

AAPHARMASYN LLC specializes in scientific research and development services, primarily supporting federal initiatives through advanced pharmaceutical and life sciences innovation. Leveraging deep expertise in process development, analytical method validation, and regulatory-compliant formulation science, the company delivers end-to-end R&D solutions tailored to the unique demands of government-funded health and biomedical programs. Their technical capabilities include GMP-aligned synthesis, stability testing, drug delivery system optimization, and data integrity frameworks aligned with 21 CFR Part 11 and ICH guidelines. As a Women-Owned Small Business and Woman-Owned Business certified firm, AAPHARMASYN brings a focused, agile approach to complex scientific challenges, emphasizing precision, reproducibility, and compliance in every phase of product development. Award history is not available to inform specific agency relationships or project types, so no definitive patterns of engagement with federal departments can be inferred from the provided data. The company’s work is likely aligned with missions under HHS, NIH, or DoD biomedical research portfolios, though direct evidence of these relationships is not present in the record. The primary NAICS code 541715 indicates a focus on research and development in the physical, engineering, and life sciences. In practice, this translates to contract-based scientific services supporting drug discovery, preclinical development, and regulatory submission readiness—particularly for entities requiring rigorous documentation and quality control systems. The firm positions itself as a nimble, specialized provider in a market dominated by large contract research organizations, offering tailored expertise in pharmaceutical process science. AAPHARMASYN LLC is a small business entity structured as a 2L, headquartered in Ann Arbor, Michigan—a region recognized for its strong life sciences ecosystem. The company holds federal certifications as a Women-Owned Small Business and Woman-Owned Business, enhancing its eligibility for set-aside contracts and underscoring its commitment to diversity in federal contracting. Its geographic presence supports collaboration with academic medical centers and federal research labs in the Great Lakes region.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Department Of Health And Human Services$728.1K68.5%
Department Of Defense$335.5K31.6%
Awards by NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)$728.1K68.5%
541713 - Research and Development in Nanotechnology$177.7K16.7%
541711 - Research and Development in Biotechnology$157.8K14.8%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in AAPHARMASYN LLC's top NAICS codes and agencies

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

about 6 hours ago

DEADLINE

N/A
View Details